07/29/2025
Highly effective HPV vaccines have been available since 2006, but they remain out of reach for many girls and women in low- and middle-income countries, where about 94% of global cervical cancer deaths occur.
In 2020, PATH launched a project to increase global HPV vaccine availability, inform policy decisions, and help overcome LMICs’ most common barriers to access. Five years later, the project has come to a close, leaving behind a long list of successes.
From World Health Organization (WHO) endorsement of the bivalent HPV vaccine Cecolin for single-dose use to a robust portfolio of health economic analyses and decision-making tools for country leaders, the world has more resources to protect girls from cervical cancer than ever before.
Read more: https://bit.ly/4l1qP3t
PATH's HPV Vaccine Safety, Immunogenicity, and Health Economics (HPV SIHE) project is coming to a close after five years--and it leaves a long list of successes behind.